Masimo to Debut Halo Index, 2011 Radical-7, and New Patient SafetyNet at American Society of Anesthesiologists Meeting

Multiple New Clinical Studies Will Also Be Presented - Including a Randomized Controlled Trial Showing the Impact of Masimo SpHb Monitoring on Blood Transfusions During Surgery

Oct 13, 2010, 08:00 ET from Masimo Corporation

IRVINE, Calif., Oct. 13 /PRNewswire/ -- Masimo (Nasdaq: MASI) announced today that several new products—including its Halo Index™, 2011 Radical-7®, and Patient Safety Net™ remote monitoring and clinician notification system—will debut in the Masimo Exhibit (#2538) at the American Society of Anesthesiologists (ASA) Annual Conference in San Diego, October 16-20, 2010.  Additional highlights of the ASA Meeting include a late-breaking randomized controlled trial on the impact of Masimo noninvasive and continuous hemoglobin (SpHb®) on blood transfusions during surgery, multiple other new clinical studies, and an educational symposium on the clinical implications of Masimo's breakthrough noninvasive monitoring technologies.

Predicting Deterioration with the Halo Index

The Halo Index is a dynamic new indicator that facilitates continuous global trending and assessment of multiple physiological parameters to quantify changes in patient status.  Ranging in value from 0-10, the Halo Index helps clinicians to better assess overall patient condition and predict deterioration in health status.  

Redefining "Radical" with the 2011 Radical-7

When it was introduced in 2000, the Radical offered a new way to think about pulse oximetry with breakthrough measure-through motion and low perfusion capabilities and features such as SatShare™ and detachable handheld with rotational display.  In 2005, the Radical-7 offered a new way of looking at patient monitoring with breakthrough rainbow® noninvasive measurement capabilities and a color display screen.  Today, the 2011 Radical-7 redefines "radical" once again with more first-ever capabilities featured this week at the ASA, such as:

  • rainbow®Acoustic Monitoring for accurate, easy-to-use, and patient-tolerant respiration rate
  • Adaptive Threshold Alarms™ for audible notification only when significant changes in physiology have occurred
  • Touch screen display for easy operation
  • On-the-fly configuration of parameter size and waveforms
  • MyView™ for personalized displays through presence detection
  • Integrated wireless 802.11 and Bluetooth for seamless connectivity

Defining General Floor Monitoring with Masimo rainbow SET & Patient SafetyNet

The Patient SafetyNet system is the only general floor monitoring system proven to help clinicians reduce rescue activations, ICU transfers, and ICU days.(1)  With new expanded capabilities debuting at the ASA, Patient SafetyNet takes enhanced and automated care to a new level with:

  • Halo Index for global trending and assessment of physiological parameter trends
  • Real-time or playback of breath sounds to assist clinicians in respiratory assessment
  • Plethysmographic and acoustic waveforms for real-time or playback patient assessment
  • MyView for personalized displays through presence detection technology
  • Clinician workflow analytics to help improve efficiency

Multiple Clinical Studies Highlight Impact of Masimo Technologies

This week's ASA meeting will also include 20 new clinical studies on Masimo technologies.  Eleven studies demonstrate the accuracy and clinical utility of SpHb monitoring, including a randomized controlled trial conducted at Massachusetts General Hospital.  

Non-CME Educational Symposium Showcases Clinical Implications of Masimo's Breakthrough Solutions

On Monday, October 18, 2010, 6:30-8:30 p.m., four anesthesiology thought-leaders will present critical insights on the clinical implications of Masimo's breakthrough solutions, including SpHb, PVI , rainbow acoustic monitoring, and Patient SafetyNet.  

The symposium will feature the following presentations and speakers:

Improving Outcomes on the General Floor with Measure-Through Motion Pulse Oximetry and Remote Monitoring and Notification

George Blike, MD—Medical Director, Patient Safety and Training Center, Dartmouth-Hitchcock Medical Center.

Goal-Directed Fluid Management with Noninvasive and Continuous Pleth Variability Index

Maxime Cannesson, MD, PhD—Associate Professor of Anesthesiology, University of California-Irvine.

Noninvasive & Continuous Hemoglobin: Clinical Application and Impact on Surgical Blood Management

Ronald Miller, MD—former Chairman, Department of Anesthesiology, University of California-San Francisco, and Editor of "Miller's Anesthesia", the definitive textbook for anesthesiology.

Accurate and Patient-Tolerant Respiration Rate with Acoustic Monitoring

Michael Ramsay, MD—Chief of Service, Department of Anesthesiology & Pain Management, Baylor University Medical Center-Dallas, and President, Baylor Research Institute.

*Some of the new product features and enhancements described have not been FDA 510(k) cleared.

(1) Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the features, performance, expanded capabilities, and commercial availability of Masimo's 2011 product technologies, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contacts:

Dana Banks

Masimo Corporation

(949) 297-7348

dbanks@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo Corporation



RELATED LINKS

http://www.masimo.com